Effects of Changing Guidelines on Prescribing Aspirin for Primary Prevention of Cardiovascular Events

References

1. 1.↵
   1. Hayden M,
   2. Pignone M,
   3. Phillips C,
   4. Mulrow C

   . Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161–72.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396–404.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Hennekens CH,
   2. Dyken ML,
   3. Fuster V

   . Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2751–3.

   OpenUrlFREE Full Text
4. 4.↵
   1. Peto R,
   2. Gray R,
   3. Collins R,
   4. et al

   . Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313–6.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129–35.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Hansson L,
   2. Zanchetti A,
   3. Carruthers SG,
   4. et al

   . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233–41.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Ridker PM,
   2. Cook NR,
   3. Lee IM,
   4. et al

   . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–304.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. De Berardis G,
   2. Sacco M,
   3. Strippoli GF,
   4. et al

   . Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Fleming T,
    2. Nissen SE,
    3. Borer JS,
    4. Armstrong PW

    . Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8–9, 2003 Gaithersburg, MD. Circulation 2004;109:e9004–5.

    OpenUrlFREE Full Text
11. 11.↵
    1. Ethier J,
    2. Bragg-Gresham JL,
    3. Piera L,
    4. et al

    . Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2007;50:602–11.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Belch J,
    2. MacCuish A,
    3. Campbell I,
    4. et al

    . The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Ogawa H,
    2. Nakayama M,
    3. Morimoto T,
    4. et al

    . Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134–41.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Baigent C,
    2. Blackwell L,
    3. Collins R,
    4. et al

    . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Fowkes FG,
    2. Price JF,
    3. Stewart MC,
    4. et al

    . Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841–8.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Goldstein LB,
    2. Adams R,
    3. Alberts MJ,
    4. et al

    . Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583–633.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Colwell JA

    . Aspirin therapy in diabetes. Diabetes Care 1997;20:1767–71.

    OpenUrlFREE Full Text
18. 18.↵
    1. Colwell JA

    . Aspirin therapy in diabetes. Diabetes Care 2004;27(Suppl 1):S72–3.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Pignone M,
    2. Alberts MJ,
    3. Colwell JA,
    4. et al

    . Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395–402.

    OpenUrlFREE Full Text
20. 20.↵
    1. Hammermeister K

    . A cardiovascular risk reduction learning community in DARTNet. University of Colorado Denver: National Heart, Lung, and Blood Institute, Recovery Act Grant, NIH Challenge Grants and Partnerships Program. 2009.
21. 21.↵
    1. D'Agostino RB Sr.,
    2. Vasan RS,
    3. Pencina MJ,
    4. et al

    . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    Wolters Kluwer Health. Master Drug Data Base v2.5. Available from: http://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/MDDB. Accessed November 15, 2013.
23. 23.↵
    1. Seshasai SRK,
    2. Wijesuriya S,
    3. Sivakumaran R,
    4. et al

    . Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:209–16.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Folks B,
    2. Leblanc WG,
    3. Staton EW,
    4. Pace WD

    . Reconsidering low-dose aspirin therapy for cardiovascular disease: a study protocol for physician and patient behavioral change. Implement Sci 2011;6:65.

    OpenUrlPubMed
25. 25.↵
    1. Rothwell PM,
    2. Wilson M,
    3. Price JF,
    4. Belch JF,
    5. Meade TW,
    6. Mehta Z

    . Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591–601.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Rothwell PM,
    2. Price JF,
    3. Fowkes FG,
    4. et al

    . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602–12.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Davis DA,
    2. Taylor-Vaisey A

    . Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408–16.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Shiffman D,
    2. Slawsky K,
    3. Fusfeld L,
    4. Devlin JJ,
    5. Goss TF

    . Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clin Ther. 2012;34:1387–94.

    OpenUrlPubMed